Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100001W36
CNY
15.77
-0.07 (-0.44%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Why is Zhejiang Jiuzhou Pharmaceutical Co., Ltd. ?

1
With ROE of 7.55%, it has a very attractive valuation with a 1.93 Price to Book Value
  • Over the past year, while the stock has generated a return of 18.12%, its profits have fallen by -25.7%
  • At the current price, the company has a high dividend yield of 2.7
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Zhejiang Jiuzhou Pharmaceutical Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Zhejiang Jiuzhou Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
13.78%
0.35
37.79%
China Shanghai Composite
15.17%
1.58
14.20%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
17.41%
EBIT Growth (5y)
14.29%
EBIT to Interest (avg)
38.95
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.23
Sales to Capital Employed (avg)
0.56
Tax Ratio
18.17%
Dividend Payout Ratio
44.44%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
15.80%
ROE (avg)
11.35%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
1.93
EV to EBIT
19.28
EV to EBITDA
12.38
EV to Capital Employed
2.24
EV to Sales
2.82
PEG Ratio
NA
Dividend Yield
2.67%
ROCE (Latest)
11.62%
ROE (Latest)
7.55%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 1,682.28 MM

RAW MATERIAL COST(Y)

Fallen by -23.71% (YoY

NET PROFIT(9M)

Higher at CNY 747.65 MM

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS

Here's what is working for Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Operating Cash Flow
Highest at CNY 1,682.28 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Profit
Higher at CNY 747.65 MM
than preceding 12 month period ended Sep 2025
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (CNY MM)

Raw Material Cost
Fallen by -23.71% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales